Compounds > bendamustine hydrochloride
Page last updated: 2024-08-25

bendamustine hydrochloride and Local Neoplasm Recurrence

bendamustine hydrochloride has been researched along with Local Neoplasm Recurrence in 102 studies

Research

Studies (102)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (9.80)29.6817
2010's46 (45.10)24.3611
2020's46 (45.10)2.80

Authors

AuthorsStudies
Ishikawa, T; Makita, M; Moriyama, T; Murakami, H; Sunami, K; Yoshioka, T1
Akay, OM; Altuntaş, F; Başcı, S; Büyükkurt, N; Dal, MS; Ferhanoğlu, B; Güneş, AK; Hindilerden, F; Kızıl Çakar, M; Korkmaz, S; Mehtap, Ö; Nalçacı, M; Özet, G; Ulaş, T; Uncu Ulu, B; Yanardağ Açık, D; Yiğenoğlu, TN; Yönal Hindilerden, İ1
Bolis, S; Botto, B; Cantonetti, M; Fabbri, A; Falchi, L; Galieni, P; Gini, G; Liberati, AM; Moretti, M; Pavone, V; Puccini, B; Pulsoni, A; Renzi, D; Rigacci, L1
Chen, YW; Cheng, CL; Chou, WC; Hong, RL; Hou, HA; Huang, TC; Ko, BS; Kuo, SH; Lin, CC; Lin, YC; Liu, JH; Lo, MY; Lu, LC; Tien, FM; Tsai, XC; Wang, YW; Wu, SJ; Yao, M1
Croft, B; Herrera, AF; Jiang, Y; Lovejoy, AF; Musick, L; Opat, S; Paulson, JN; Ray, J; Sehn, LH; Tracy, S1
Buffardi, S; De Vito, R; Del Bufalo, F; Di Matteo, A; Di Ruscio, V; Locatelli, F; Mariggiò, E; Paganelli, V; Pagliara, D; Parasole, R; Petruzziello, F; Stocchi, F; Strocchio, L; Vinti, L1
Cahill, KE; Smith, SM1
Ayers, A; Crombie, JL; Feng, L; Gouni, S; Hess, B; Ip, A; Iqbal, M; Kamdar, MK; Khurana, A; Lin, Y; Merryman, RW; Neelapu, SS; Rosenthal, AC; Strati, P; Watson, G1
Chen, D; Chen, Y; Gao, J; Jia, Y; Tao, H; Wang, F; Wu, P; Zhou, Z1
Husnain, M; Katsanis, E; Khurana, S; Kovacs, K; Roe, DJ; Simpson, RJ; Stea, B; Truscott, L1
Afanasyev, B; Beynarovich, A; Borzenkova, E; Kondakova, E; Kozlov, A; Kulagin, A; Lepik, K; Mikhailova, N; Moiseev, I; Pirogova, O; Stelmakh, L; Volkov, N; Zalyalov, Y; Zubarovskaya, L1
Bashey, A; Brown, S; Holland, HK; Jackson, KC; Morris, LE; Shegda, N; Solh, M; Solomon, SR; Zhang, X1
Beitinjaneh, A; Bouabdallah, K; Fang, X; Flinn, IW; Goy, A; Hill, BT; Holmes, H; Houot, R; Jacobson, CA; Jaglowski, S; Kersten, MJ; Khanal, R; Kloos, I; Locke, FL; McSweeney, PA; Miklos, DB; Munoz, J; Pagel, JM; Peng, W; Reagan, PM; Shen, RR; Siddiqi, R; Timmerman, JM; Topp, MS; Wang, M1
Edina, BC; Rinaldi, I1
Frascione, PMM; Novo, M; Paruzzo, L; Poletto, S; Vitolo, U1
Cheng, LL; Cheng, S; Wang, L; Xu, PP; Zhang, MC; Zhao, F; Zhao, WL; Zheng, Z1
Bastos Oreiro, M; Buño, I; Carbonell, D; Chicano, M; Díaz Crespo, FJ; Diez Martín, JL; Kwon, M; Martín Rojas, R; Martínez-Laperche, C; Menárguez, J; Muñiz, P; Sanz-Villanueva, L; Suárez-González, J1
Kameoka, Y1
Agbetiafa, K; Amorim, S; Aubrais, R; Banos, A; Bellal, M; Besson, C; Bijou, F; Bonnet, C; Bouabdallah, K; Brice, P; Chartier, L; Chauchet, A; Cluzeau, T; Daguindau, N; Damaj, G; Delapierre, B; Durot, E; Fouillet, L; Gaulard, P; Herbaux, C; Laribi, K; Le Calloch, R; Parrens, MC; Schiano, JM; Sibon, D; Tournilhac, O1
Cen, H; Ding, K; Gao, Y; Huang, H; Lin, J; Liu, Y; Lv, F; Ma, L; Song, B; Tang, X; Wang, S; Wang, Y; Wu, D; Wu, J; Xiang, Y; Xu, W; Yang, Y; Ye, X; Yu, H; Zhang, F; Zhang, Q; Zhao, Y; Zhou, J1
Amoroso, L; Beishuizen, A; Buffardi, S; Cole, PD; Cooper, S; Daw, S; Drachtman, RA; Francis, S; Harker-Murray, P; Hoppe, BS; Kelly, KM; Leblanc, T; Leger, KJ; Lisano, J; Mascarin, M; Mauz-Körholz, C; Michel, G; Rigaud, C; Sacchi, M1
Al Batran, M; Al Darweesh, M; Al Garni, A; Al Hashmi, H; Al Naim, A; Al Zayer, M; Kaloyannidis, P; Kanfar, S1
Andreadis, C; Banerjee, R; Beitinjaneh, AM; Dahiya, S; Deol, A; Dorritie, KA; Frank, MJ; Ghobadi, A; Goy, A; Hill, BT; Jacobs, MT; Jain, MD; Jain, P; Lekakis, L; Lin, Y; Locke, FL; Maurer, MJ; Mcguirk, JP; Miklos, DB; Munoz, JL; Neelapu, SS; Oluwole, OO; Paludo, J; Rapoport, AP; Shah, B; Vose, JM; Wang, ML; Wang, T; Wang, Y1
Ishio, T; Izumiyama, K; Kobayashi, M; Kondo, T; Mori, A; Morioka, M; Muraki, H; Saito, M; Tsukamoto, S; Yokoyama, E1
Bedini, A; Bettelli, F; Dolci, G; Franceschini, E; Fregni-Serpini, G; Grottola, A; Guaraldi, G; Luppi, M; Meschiari, M; Mussini, C; Pecorari, M; Pellegrino, M; Perno, CF; Sarti, M; Todisco, V1
Arcari, A; Botto, B; Bruna, R; Celli, M; Cencini, E; Chini, C; Di Rocco, A; Evangelista, A; Ferrante, M; Ferrero, S; Ghiggi, C; Merli, F; Moia, R; Patti, C; Pileri, SA; Puccini, B; Quaglia, FM; Re, A; Sciarra, R; Spina, M; Stelitano, C; Tani, M; Tisi, MC; Visco, C; Volpetti, S; Zambello, R; Zanni, M; Zilioli, VR1
Bartlett, NL; Cashen, A; Edwin, N; Fehniger, TA; Ghobadi, A; Guy, DG; Kahl, BS; Patel, DA; Shah, NM; Trinkaus, K; Wan, F; Watkins, M1
Crews, KR; Flerlage, JE; Niloy, KK; Panetta, JC; Purvis, KN; Swanson, HD; Zhou, Y1
Ballerini, F; Bari, A; Califano, C; Capponi, M; Catellani, H; Conconi, A; Federico, M; Galimberti, S; Ghiggi, C; Gini, G; Liberati, AM; Luminari, S; Manni, M; Mannina, D; Marcheselli, L; Massaia, M; Merli, M; Musto, P; Musuraca, G; Nizzoli, ME; Pastore, D; Pennese, E; Perrone, T; Pulsoni, A; Re, F; Skrypets, T; Stefani, PM; Usai, SV; Vitolo, U1
Ballestrero, A; Calabrese, M; Ceccardi, A; Cuccarolo, P; Dameri, M; Garlaschi, A; Gristina, L; Stabile, M; Tagliafico, A; Valente, I; Zoppoli, G1
Fu, CC; Jin, S; Ma, X; Shang, JJ; Wang, J; Wu, DP; Yao, Y1
Chen, W; Gong, Q; Ma, J; Xia, Y; Zhao, D; Zhen, B1
Caballero, MD; Canales, M; Capote, FJ; Durán, S; Giraldo, P; Gutiérrez, A; López, A; Márquez, JA; Martín, A; Montalbán, C; Peñalver, FJ; Ramírez, MJ; Rodríguez-Caravaca, G; Salar, A; Sánchez, B; Sancho, JM; Terol, MJ1
Crosbie, N; Eyre, TA; Frewin, R; Lambert, J; McCulloch, R; McMillan, A; Phillips, N; Quaglia, FM; Rule, S; Tucker, DL; Visco, C1
Bhutani, D; Comenzo, RL; Lagos, GG; Landau, H; Lentzsch, S; Osman, K; Pan, S; Pregja, S; Sanchorawala, V; Zonder, JA1
Benedetti, L; Bergamaschi, M; Briani, C; Demichelis, C; Ferrari, S; Garnero, M; Massa, F; Pesce, G; Schenone, A; Zuppa, A1
Amaya, ML; Jimeno, A; Kamdar, M1
Advani, RH; Ansell, SM; Cescon, TP; Chang, JE; Cheema, PS; Dy, PA; Evens, AM; Gascoyne, RD; Habermann, TM; Hong, F; Kahl, BS; O'Brien, TE; Quon, A; Ranheim, EA; Winter, JN; Witzig, TE1
Izumi, T; Kato, S; Kawamura, T; Kimura, F; Kobayashi, A; Kobayashi, S; Maekawa, T; Nagao, S; Ogata, H; Okada, Y; Saito, K; Sato, K; Sone, T; Tachi, N; Takada, K; Takano, K; Teramoto, M1
Cheng, B; Connors, JM; Crump, M; Deng, C; Kuruvilla, J; Lue, JK; Ma, H; Marchi, E; Montanari, F; O'Connor, OA; Savage, KJ; Sawas, A; Villa, D1
Akiba, K; Hashida, T; Hirano, T; Hosohata, K; Ikesue, H; Ishikawa, T; Maegawa, N; Miyasaka, M; Mori, Y; Muroi, N; Nakamura, T; Shimomura, Y; Takano, A; Uchida, M; Yamaguchi, Y1
Alpdogan, SO; Carabasi, M; Chapman, A; DiMeglio, M; Filicko-OHara, J; Flomenberg, N; Gaballa, S; Ghimire, S; Gong, J; Martinez-Outschoorn, U; Pan, J; Porcu, P; Pro, B; Ramirez, M; Rose, L; Wagner, JL; Weiss, M1
Ardeshna, KM; Carpenter, B; Daw, S; Grandage, V; Hough, R; Humphries, P; Lambert, J; McMillan, A; Menezes, L; O'Neill, AT; Shah, R; Townsend, W; Virchis, A; Von Both, K1
Boyd, TE; Cannan, M; Fellague-Chebra, R; Feng, X; Kingsley, E; Lyons, RM; Moezi, M; Richards, D; Sharman, J; Shtivelband, M1
Badillo, M; Chen, W; Feng, L; Graham, V; Jain, P; Lee, HC; Lee, HJ; Lu, R; Manasanch, EE; Oriabure, O; Orlowski, RZ; Wang, ML1
Du, X; Han, XH; Hellriegel, E; Hong, XN; Huang, HQ; James, L; Jia, YQ; Jin, J; Ke, XY; Li, W; Liu, AC; Liu, DH; Shen, ZX; Shi, YK; Wu, DP; Wu, JQ; Xiao, XB; Xu, W; Yang, JL; Yang, SM; Zhang, LS; Zhang, MZ; Zhou, DB; Zhu, J1
Aquino, S; Boccadoro, M; Corradini, P; Einsele, H; Engelhardt, M; Gay, F; Gentili, S; Gramatzki, M; Günther, A; Montefusco, V; Offidani, M; Palumbo, A; Patriarca, F; Pönisch, W; Salvini, M; Schub, N; Sonneveld, P; Spada, S; Straka, C; Wäsch, R1
Abe, R; Amagai, M; Funakoshi, T; Kikuchi, T; Koda, Y; Kurihara, Y; Mori, T; Okamoto, S; Sato, H; Shimizu, T; Tsunoda, K; Yamagami, J1
Iwasaki, H; Kadowaki, M; Kohno, K; Takase, K; Yamasaki, S1
Alenxandrova, K; Arfi-Rouche, J; Bourhis, JH; Castilla-Llorente, C; Danu, A; Ghez, D; Khalife-Saleh, N; Koscielny, S; Lapierre, V; Lazarovici, J; Legoupil, C; Michot, JM; Pilorge, S; Ribrag, V; Saleh, K1
Chan, EKH; Chanan-Khan, A; Cramer, P; Diels, J; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Howes, A; Janssens, A; Loscertales, J; Mahler, M; Rule, S; Salman, M; Santucci-Silva, R; Sengupta, N; Traina, S1
Angrilli, F; Chaffee, KG; Chiarenza, A; Ciolli, S; Cortelezzi, A; Coscia, M; Cutrona, G; D'Arrigo, G; Del Poeta, G; Del Principe, MI; Di Raimondo, F; Di Renzo, N; Ferrarini, M; Foà, R; Gaidano, G; Gentile, M; Giordano, A; Herishanu, Y; Innocenti, I; Laurenti, L; Mauro, FR; Molica, S; Morabito, F; Neri, A; Parikh, SA; Polliack, A; Recchia, AG; Reda, G; Rossi, D; Shanafelt, TD; Shvidel, L; Tadmor, T; Tripepi, G; Uccello, G; Vigna, E; Zirlik, K1
Bosch, F; Böttcher, S; Foà, R; Gresko, E; Ilhan, O; Knauf, W; Leblond, V; Lundberg, L; Mikuskova, E; Moore, T; Morris, T; Renner, C; Robson, S; Stilgenbauer, S; Tausch, E; Woszczyk, D1
Bernaards, C; Guzauskas, GF; Krivasi, T; Masaquel, A; Reyes, C; Veenstra, DL1
Agarwal, S; Cordero, J; de Vos, S; Dunbar, M; Enschede, SH; Flowers, CR; Fowler, N; Kozloff, M; Nastoupil, LJ; Nolan, C; Petrich, AM; Reid, E; Ross, JA; Salem, AH; Swinnen, LJ; Verdugo, M; Wang, D; Zhou, L1
Armitage, JO; Kallam, A1
Blajer-Olszewska, B; Chojnacki, T; Drozd-Sokołowska, J; Długosz-Danecka, M; Hus, I; Jurczak, W; Jurczyszyn, A; Puła, B; Raźny, M; Romejko-Jarosińska, J; Taszner, M1
Do, YR; Hong, JY; Hyun, SY; Jo, JC; Kim, JA; Kim, MK; Kim, WS; Koh, YI; Lee, SS; Lee, WS; Oh, YH; Park, BB; Suh, C; Won, JH; Yang, DH1
Cheson, BD; Ujjani, C1
Cabanillas, F; Rivera-Rodriguez, N1
Amino, N; Kaneko, N; Kita, A; Kuromitsu, S; Mitsuoka, K; Miyoshi, S; Mori, M; Yamanaka, K1
Chamberlain, MC1
Carbone, DP; Horn, L; Hutchison, AS; Johnson, DH; Keedy, VL; Lammers, PE; Li, CI; Sandler, A; Shyr, Y1
Cavo, M; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT1
Bramanti, S; Bruno-Ventre, M; Castagna, L; Ciceri, F; Corti, C; Crocchiolo, R; Gandolfi, S; Marktel, S; Peccatori, J; Sala, E; Santoro, A; Sarina, B1
Bellam, N; Eisenfeld, AJ; Feldman, T; Gopal, AK; Goy, A; Green, DJ; Griffin, M; Mato, AR; Stromatt, SC; Tarantolo, SR1
Blum, KA; Byrd, JC; Christian, B; Flynn, J; Jaglowski, S; Jenkins, C; Jones, JA; Lozanski, G; Maddocks, K; Porcu, P; Wei, L1
Anglaret, B; Avet-Loiseau, H; Banos, A; Benboubker, L; Benramdane, R; Casassus, P; Chaleteix, C; Cony-Makhoul, P; Decaux, O; Dejoie, T; Dib, M; Fitoussi, O; Fontan, J; Garderet, L; Hulin, C; Jardel, H; Kolb, B; Leleu, X; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Pétillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Traullé, C; Vilque, JP1
Ando, K; Kim, WS; Niitsu, N; Ogura, M; Suh, C; Tateishi, U; Tatsumi, M; Terauchi, T; Tobinai, K1
Atta, J; Buske, C; Dreyling, M; Hess, G; Keller, U; Kirschey, S; Klapper, W; Medler, C; Ruckes, C; Scholz, CW; Theobald, M; van Oordt, C; Witzens-Harig, M1
Aisa, Y; Chen, K; Hagihara, M; Ishida, A; Masuda, Y; Matsumoto, K; Miyakawa, Y; Nakajima, H; Nakaya, A; Nakazato, T; Okamoto, S; Shimizu, T; Takayama, N; Tsukada, Y; Ueno, H; Watanabe, K; Yamada, Y; Yano, T; Yokoyama, K1
Argnani, L; Broccoli, A; Cascavilla, N; Corradini, P; Hohaus, S; Merli, F; Motta, G; Tani, M; Vitolo, U; Viviani, S; Zinzani, PL1
Hänel, M; Schmeel, FC; Schmeel, LC; Schmidt-Wolf, IG; Stöhr, E1
Fukuhara, S; Kitahara, H; Kobayashi, Y; Maeshima, AM; Makita, S; Maruyama, D; Miyamoto, K; Munakata, W; Saito, H; Suzuki, T; Taniguchi, H; Tobinai, K1
Illés, Á; Jóna, Á; Miltényi, Z; Simon, Z; Udvardy, M1
Inayat, F; Law, JK; Myers-Gurevitch, PM; Perlman, AS; Seshan, SV1
Arcari, A; Bernuzzi, P; Cabras, MG; Carli, G; Chiappella, A; Cox, MC; Gentile, M; Ghio, F; Ilariucci, F; Marasca, R; Marino, D; Musto, P; Santagostino, A; Savini, P; Spina, M; Tani, M; Valenti, V; Vallisa, D; Zambello, R; Zanlari, L1
Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S1
Bouabdallah, K; Cheson, BD; Chua, N; Delwail, V; Dimier, N; Dueck, G; Fingerle-Rowson, G; Fowler, N; Gribben, J; Lennard, A; Lugtenburg, PJ; Mayer, J; Press, O; Salles, G; Sehn, LH; Trněný, M; Wassner-Fritsch, E1
Czuczman, MS; Graf, DA; Lamonica, D; Munteanu, MC1
Nagai, Y; Nagashima, K; Sugita, Y; Tanaka, H1
Chamberlain, MC; Colman, H; Kim, BT; Raizer, J1
Cheson, BD; Cohen, P; Herst, JA; Lemieux, B; Robinson, KS; Schwartzberg, LS; Tulpule, A; van der Jagt, RH; Williams, ME1
Ishizawa, K; Ogura, M; Tateishi, U; Tatsumi, M; Terauchi, T; Tobinai, K1
Armitage, JO; Bernstein, SH; Blumel, S; Fisher, RI; Friedberg, JW; Grant, S; Kelly, JL; Leonard, JP; Liesveld, J; Peterson, D; Proia, NK; Rich, L; Vose, JM; Young, F1
Chamberlain, MC; Johnston, SK1
Amin, B; Cashen, AF; Cheson, BD; Fowler, N; Jacobs, SA; Kahl, BS; Lee, P; Letzer, J; Matous, JV; Parasuraman, S; Rosen, P; Saleh, A; Shi, H; Smith, S; Williams, ME1
Alam, S; Layman, R; Lustberg, M; Reinbolt, RE; Shapiro, C1
Chan, M; Detroye, A; Ellis, T; Johnson, A; Lesser, GJ; McMullen, K; Mott, R; Renfrow, JJ; Tatter, S1
Banos, A; Béné, MC; Bouabdallah, K; Bubenheim, M; Cartron, G; Choufi, B; Cony-Makhoul, P; Damaj, G; Diouf, M; Gressin, R; Gyan, E; Houot, R; Jaccard, A; Joly, B; Lamy, T; Le Gouill, S; Marolleau, JP; Martin, A; Park, S; Saad, A; Sanhes, L; Schiano-de Collela, JM; Schmidt-Tanguy, A; Tournilhac, O; Vilque, JP; Voillat, L1
Beijnen, JH; Bond, M; D'Andrea, D; Darwish, M; Dubbelman, AC; Hellriegel, E; Robertson, P; Rosing, H; Schellens, JH1
Aivado, M; Burger, J; Finke, J; Haas, R; Henze, L; Schulte, K1
Hoelzer, D; Mitrou, PS; Rummel, MJ1
Hoelzer, D; Kim, SZ; Mitrou, PS; Rost, A; Schuppert, H; Seipelt, G; Weidmann, E1
Bremer, K1
Einsele, H; Haen, M; Hebart, H; Knop, S; Schwedes, R; Straka, C1
Bergmann, MA; Boening, L; Emmerich, B; Goebeler, ME; Hallek, MJ; Herold, M; Ruelfs, C; Wilhelm, M1
Bathe, K; Bottke, D; Hinkelbein, W; Wiegel, T1
Beyer, J; Bokemeyer, C; Casper, J; Gerl, A; Kanz, L; Kollmannsberger, C; Kuczyk, M; Rick, O; Rie, C; Schleucher, N; Sosada, M1
Heider, A; Niederle, N1

Reviews

8 review(s) available for bendamustine hydrochloride and Local Neoplasm Recurrence

ArticleYear
Follicular Lymphoma: a Focus on Current and Emerging Therapies
    Oncology (Williston Park, N.Y.), 2022, 02-08, Volume: 36, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Genetic Testing; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Follicular; Maintenance Chemotherapy; Morpholines; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Prednisone; Pyridones; Rituximab; Sulfonamides; Vincristine

2022
Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
    Acta medica Indonesiana, 2022, Volume: 54, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prednisone; Randomized Controlled Trials as Topic; Rituximab; Vincristine

2022
Treatment strategies for patients with diffuse large B-cell lymphoma.
    Cancer treatment reviews, 2022, Volume: 110

    Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Rituximab; Vincristine

2022
The optimal management of follicular lymphoma: an evolving field.
    Drugs, 2013, Volume: 73, Issue:13

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Induction Chemotherapy; Lymphoma, Follicular; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prednisone; Prognosis; Rituximab; Vincristine

2013
Recent advances in the management of mantle cell lymphoma.
    Current opinion in oncology, 2013, Volume: 25, Issue:6

    Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Child; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Patient Selection; Phosphatidylinositol 3-Kinases; Prognosis; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome

2013
Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local

2015
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
    Vnitrni lekarstvi, 2016, Volume: 62, Issue:1

    Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia

2016
Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
    Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prednisolone; Prognosis; Remission Induction; Rituximab; Survival Rate; Vincristine

2002

Trials

44 trial(s) available for bendamustine hydrochloride and Local Neoplasm Recurrence

ArticleYear
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
    Annals of hematology, 2022, Volume: 101, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoconjugates; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Treatment Outcome; Young Adult

2022
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.
    Blood advances, 2022, 03-22, Volume: 6, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Circulating Tumor DNA; Humans; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Rituximab

2022
Feasibility and Efficacy of Partially Replacing Post-Transplantation Cyclophosphamide with Bendamustine in Pediatric and Young Adult Patients Undergoing Haploidentical Bone Marrow Transplantation.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:7

    Topics: Adolescent; Bendamustine Hydrochloride; Bone Marrow Transplantation; Child; Cyclophosphamide; Ethnicity; Feasibility Studies; Graft vs Host Disease; Humans; Minority Groups; Neoplasm Recurrence, Local; Young Adult

2022
High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:8

    Topics: Bendamustine Hydrochloride; Cytarabine; Drug Therapy, Combination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous

2022
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
    Blood, 2023, 04-27, Volume: 141, Issue:17

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Nivolumab; Treatment Outcome; Young Adult

2023
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.
    Hematological oncology, 2023, Volume: 41, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Follicular; Neoplasm Recurrence, Local; Prednisone; Rituximab; Vincristine

2023
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase
    Cancer medicine, 2019, Volume: 8, Issue:16

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Progression-Free Survival; Rituximab; Salvage Therapy

2019
Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 05-01, Volume: 38, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Treatment Outcome; Vomiting

2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 09-01, Volume: 26, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lenalidomide; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Rituximab; Young Adult

2020
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/I
    Leukemia & lymphoma, 2020, Volume: 61, Issue:12

    Topics: Bendamustine Hydrochloride; Brentuximab Vedotin; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Progression-Free Survival

2020
Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Carboplatin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy

2021
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Rituximab

2021
A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma.
    American journal of hematology, 2021, 07-01, Volume: 96, Issue:7

    Topics: Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Treatment Outcome

2021
Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study.
    Chinese medical journal, 2021, May-06, Volume: 134, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; China; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prospective Studies; Rituximab

2021
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
    Cancer, 2021, 09-15, Volume: 127, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides

2021
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the H
    Leukemia & lymphoma, 2018, Volume: 59, Issue:9

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Blind Method; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Physical Fitness; Piperidines; Pyrazoles; Pyrimidines; Quality of Life; Rituximab; Surveys and Questionnaires

2018
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study.
    Leukemia, 2018, Volume: 32, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Remission Induction; Rituximab; Salvage Therapy; Survival Rate

2018
Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
    Journal of medical economics, 2018, Volume: 21, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cost-Benefit Analysis; Female; Humans; Lymphoma, Follicular; Male; Medicare; Neoplasm Recurrence, Local; Progression-Free Survival; Quality-Adjusted Life Years; Rituximab; United States

2018
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 09-01, Volume: 29, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Rituximab; Salvage Therapy; Sulfonamides

2018
A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial).
    Leukemia & lymphoma, 2019, Volume: 60, Issue:13

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carboplatin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Progression-Free Survival; Salvage Therapy; Thrombocytopenia; Young Adult

2019
Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrogen Mustard Compounds; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate

2014
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.
    Investigational new drugs, 2014, Volume: 32, Issue:6

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Immunoglobulin G; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Recombinant Fusion Proteins; Rituximab; Tetraspanins; Treatment Outcome

2014
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
    Blood, 2015, Jan-08, Volume: 125, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Young Adult

2015
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
    Haematologica, 2015, Volume: 100, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Pyrazines; Survival Rate

2015
Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Cancer science, 2015, Volume: 106, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Rituximab; Tomography, X-Ray Computed; Tumor Burden; Young Adult

2015
Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
    Leukemia, 2015, Volume: 29, Issue:8

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrogen Mustard Compounds; Prognosis; Prospective Studies; Remission Induction; Rituximab; Safety; Sirolimus; Survival Rate

2015
A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
    International journal of hematology, 2015, Volume: 101, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Rituximab; Treatment Outcome; Young Adult

2015
Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
    Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:2 Suppl 1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Cohort Studies; Dacarbazine; Female; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Neoplasm Recurrence, Local

2016
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:8

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Rituximab; Survival Rate

2016
18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017, Volume: 58, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Recurrence; Reproducibility of Results; Rituximab; Sensitivity and Specificity; Survival Rate; Treatment Outcome

2017
Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
    Journal of neuro-oncology, 2017, Volume: 131, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome

2017
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-20, Volume: 26, Issue:27

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Gastrointestinal Diseases; Headache; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab

2008
Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study.
    Cancer science, 2011, Volume: 102, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials, Phase II as Topic; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve

2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
    Blood, 2011, Mar-10, Volume: 117, Issue:10

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab

2011
Salvage therapy with single agent bendamustine for recurrent glioblastoma.
    Journal of neuro-oncology, 2011, Volume: 105, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Salvage Therapy

2011
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Sep-01, Volume: 29, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome

2011
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrogen Mustard Compounds; Prognosis; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate

2013
Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy.
    Drugs in R&D, 2013, Volume: 13, Issue:1

    Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Carbon Radioisotopes; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Nitrogen Mustard Compounds; Recurrence

2013
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Remission Induction; Survival Rate; Treatment Outcome

2002
High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Journal of cancer research and clinical oncology, 2002, Volume: 128, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Remission Induction; Salvage Therapy; Survival Rate

2002
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
    Haematologica, 2005, Volume: 90, Issue:10

    Topics: Aged; Aged, 80 and over; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Survival Analysis

2005
Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2007, Volume: 183, Issue:3

    Topics: Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Otorhinolaryngologic Neoplasms

2007
Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer.
    Anti-cancer drugs, 2000, Volume: 11, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cisplatin; Cross-Linking Reagents; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Germinoma; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds

2000
Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.
    Anti-cancer drugs, 2001, Volume: 12, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Survival Analysis

2001

Other Studies

50 other study(ies) available for bendamustine hydrochloride and Local Neoplasm Recurrence

ArticleYear
Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
    Acta medica Okayama, 2021, Volume: 75, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Japan; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Retrospective Studies; Rituximab; Salvage Therapy

2021
Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.
    Journal of chemotherapy (Florence, Italy), 2022, Volume: 34, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome

2022
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
    Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Transplantation, Autologous; Treatment Outcome

2022
Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma.
    Pediatric blood & cancer, 2022, Volume: 69, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Young Adult

2022
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.
    Blood advances, 2022, 05-10, Volume: 6, Issue:9

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab

2022
Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
    Medicine, 2022, Mar-04, Volume: 101, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Gastroscopy; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome; Ultrasonography

2022
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.
    International journal of hematology, 2022, Volume: 116, Issue:3

    Topics: Adult; Bendamustine Hydrochloride; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 01-20, Volume: 41, Issue:3

    Topics: Adult; Bendamustine Hydrochloride; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen

2023
[Analysis of clinical factors of bendamustine combined with rituximab in the treatment of recurrent follicular lymphoma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022, 06-14, Volume: 43, Issue:6

    Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Chronic Disease; Humans; Lymphoma, Follicular; Neoplasm Recurrence, Local; Rituximab

2022
EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.
    BMC cancer, 2022, Sep-14, Volume: 22, Issue:1

    Topics: Bendamustine Hydrochloride; Biomarkers; Cyclophosphamide; Doxorubicin; Enhancer of Zeste Homolog 2 Protein; Humans; Lymphoma, Follicular; Mutation; Neoplasm Recurrence, Local; Prednisone; Retrospective Studies; Rituximab; Vincristine

2022
[Standard treatment and future perspectives for follicular lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Quality of Life; Rituximab

2022
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
    Blood advances, 2023, 10-10, Volume: 7, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Chronic Disease; Hodgkin Disease; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome

2023
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
    Cancer, 2023, 02-15, Volume: 129, Issue:4

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chronic Disease; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Rituximab; Treatment Outcome; Young Adult

2023
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
    Leukemia & lymphoma, 2023, Volume: 64, Issue:3

    Topics: Bendamustine Hydrochloride; Brentuximab Vedotin; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 05-10, Volume: 41, Issue:14

    Topics: Adult; Antigens, CD19; Bendamustine Hydrochloride; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen

2023
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
    Annals of hematology, 2023, Volume: 102, Issue:6

    Topics: Antibodies, Monoclonal, Murine-Derived; Antibodies, Viral; Bendamustine Hydrochloride; COVID-19; COVID-19 Vaccines; Humans; Immunity, Humoral; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Rituximab; SARS-CoV-2; Vaccination

2023
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
    Infection, 2023, Volume: 51, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; COVID-19; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Neoplasm Recurrence, Local; Rituximab; SARS-CoV-2

2023
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL.
    Blood advances, 2023, 08-08, Volume: 7, Issue:15

    Topics: Adult; Aged; Bendamustine Hydrochloride; Cytarabine; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Prospective Studies; Rituximab

2023
Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.
    Clinical lymphoma, myeloma & leukemia, 2023, Volume: 23, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Pilot Projects; Rituximab

2023
Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma.
    Cancer chemotherapy and pharmacology, 2023, Volume: 92, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Child; Doxorubicin; Hodgkin Disease; Humans; Mechlorethamine; Neoplasm Recurrence, Local

2023
Complete pathological response of hormone receptor positive invasive breast cancer in a patient with multiple myeloma treated with ixazomib.
    Tumori, 2023, Volume: 109, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Breast Neoplasms; Dexamethasone; Female; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence

2023
[Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2023, Jun-14, Volume: 44, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local

2023
Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma.
    Journal of comparative effectiveness research, 2023, Volume: 12, Issue:12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cost-Benefit Analysis; East Asian People; Humans; Lymphoma, Follicular; Neoplasm Recurrence, Local; Quality of Life

2023
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
    British journal of haematology, 2020, Volume: 189, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Rituximab

2020
Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy.
    Journal of the neurological sciences, 2020, 06-15, Volume: 413

    Topics: Bendamustine Hydrochloride; Hematologic Neoplasms; Humans; Myelin-Associated Glycoprotein; Neoplasm Recurrence, Local; Polyneuropathies; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Rituximab

2020
Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
    Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:4

    Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Rituximab

2020
[Bendamustine and rituximab combination therapy for recurrent indolent B-cell lymphomas: a retrospective single-institution study].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab

2020
Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma.
    Biological & pharmaceutical bulletin, 2020, Oct-01, Volume: 43, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug Resistance, Neoplasm; Female; Humans; Incidence; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Risk Assessment; Risk Factors; Rituximab

2020
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
    British journal of haematology, 2021, Volume: 192, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Female; Hodgkin Disease; Humans; Male; Neoplasm Recurrence, Local; Treatment Outcome; Young Adult

2021
Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
    Annals of hematology, 2017, Volume: 96, Issue:7

    Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lymphoma, Follicular; Neoplasm Grading; Neoplasm Recurrence, Local; Paraneoplastic Syndromes; Pemphigus; Radiodermatitis; Rituximab; Severity of Illness Index; Skin; Treatment Outcome; Tumor Burden

2017
Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine.
    Annals of hematology, 2017, Volume: 96, Issue:7

    Topics: Academic Medical Centers; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Administration Schedule; Female; Follow-Up Studies; Ganciclovir; Humans; Injections, Intravenous; Intravitreal Injections; Japan; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Opportunistic Infections; Retrospective Studies

2017
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Case-Control Studies; Cytarabine; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2018
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
    Leukemia, 2018, Volume: 32, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Cohort Studies; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Rituximab; Severity of Illness Index; Survival Rate

2018
Venetoclax in chronic lymphocytic leukaemia: a possible cure?
    The Lancet. Oncology, 2018, Volume: 19, Issue:9

    Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Sulfonamides

2018
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Pharmacological reports : PR, 2019, Volume: 71, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Transplantation, Autologous

2019
Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Apr-01, Volume: 20, Issue:7

    Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; Mice; Naphthoquinones; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Rituximab; Survivin; Xenograft Model Antitumor Assays

2014
Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.
    Journal of neuro-oncology, 2014, Volume: 118, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Central Nervous System Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Retrospective Studies; Salvage Therapy; Treatment Outcome

2014
Bendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphocytes; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Transplantation Conditioning

2014
Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brentuximab Vedotin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Failure; Young Adult

2015
Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate

2015
Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
    Blood cancer journal, 2015, Oct-23, Volume: 5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab

2015
[Novel treatment options in relapsed and refracter Hodgkin lymphomas].
    Orvosi hetilap, 2015, Nov-08, Volume: 156, Issue:45

    Topics: Adult; Antineoplastic Agents; B7-H1 Antigen; Bendamustine Hydrochloride; Brentuximab Vedotin; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hungary; Immunoconjugates; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Sclerosis; Survival Analysis; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome

2015
Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
    Clinical nephrology, 2016, Volume: 85, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Colonic Neoplasms; Diagnosis, Differential; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nephrosis, Lipoid; Proteinuria; Rituximab

2016
Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:8

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Disease-Free Survival; Female; Follow-Up Studies; Humans; Italy; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome

2016
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
    Prescrire international, 2016, Volume: 25, Issue:170

    Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine

2016
Immune pancytopenia after chemotherapy in a patient with diffuse large B-cell lymphoma.
    BMJ case reports, 2016, Sep-20, Volume: 2016

    Topics: Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bendamustine Hydrochloride; Bone Marrow; Female; Humans; Japan; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Pancytopenia; Prednisolone; Rituximab; Treatment Outcome

2016
Pneumocystis jiroveci Pneumonia in an Atypical Host.
    Clinical breast cancer, 2012, Volume: 12, Issue:2

    Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bevacizumab; Breast Neoplasms; CD4 Lymphocyte Count; Clinical Trials, Phase I as Topic; Dexamethasone; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Paclitaxel; Pneumocystis carinii; Pneumonia, Pneumocystis; Quinazolines; Trimethoprim, Sulfamethoxazole Drug Combination

2012
Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.
    Journal of neuro-oncology, 2012, Volume: 107, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds

2012
Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
    Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13

    Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Cladribine; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Vidarabine

2002
The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.
    Haematologica, 2005, Volume: 90, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds

2005